{"id":1057,"date":"2026-11-19T08:38:50","date_gmt":"2026-11-19T07:38:50","guid":{"rendered":"https:\/\/event.eortc.org\/ena2026\/?page_id=1057"},"modified":"2026-11-19T08:50:01","modified_gmt":"2026-11-19T07:50:01","slug":"news","status":"publish","type":"page","link":"https:\/\/event.eortc.org\/ena2026\/news\/","title":{"rendered":"News"},"content":{"rendered":"<p><div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-1 fusion-flex-container has-pattern-background has-mask-background nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-border-radius-top-left:63px;--awb-border-radius-top-right:63px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-overflow:hidden;--awb-padding-bottom:0px;--awb-margin-top:-63px;--awb-margin-bottom:0px;--awb-margin-top-small:-53px;--awb-background-color:var(--awb-color6);--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-end fusion-flex-content-wrap\" style=\"max-width:1248px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-0 fusion_builder_column_1_1 1_1 fusion-flex-column\" style=\"--awb-bg-color:var(--awb-color6);--awb-bg-color-hover:var(--awb-color6);--awb-bg-size:cover;--awb-width-large:100%;--awb-margin-top-large:0px;--awb-spacing-right-large:1.92%;--awb-margin-bottom-large:8%;--awb-spacing-left-large:1.92%;--awb-width-medium:100%;--awb-order-medium:0;--awb-spacing-right-medium:1.92%;--awb-spacing-left-medium:1.92%;--awb-width-small:100%;--awb-order-small:0;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;\" data-scroll-devices=\"small-visibility,medium-visibility,large-visibility\"><div class=\"fusion-column-wrapper fusion-column-has-shadow fusion-flex-justify-content-flex-start fusion-content-layout-column\"><\/div><\/div><\/div><\/div><div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-2 fusion-flex-container has-pattern-background has-mask-background nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-margin-bottom:2%;--awb-background-color:var(--awb-color6);--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap\" style=\"max-width:1248px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-1 fusion_builder_column_1_1 1_1 fusion-flex-column\" style=\"--awb-bg-size:cover;--awb-width-large:100%;--awb-margin-top-large:0px;--awb-spacing-right-large:1.92%;--awb-margin-bottom-large:20px;--awb-spacing-left-large:1.92%;--awb-width-medium:100%;--awb-order-medium:0;--awb-spacing-right-medium:1.92%;--awb-spacing-left-medium:1.92%;--awb-width-small:100%;--awb-order-small:0;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;\"><div class=\"fusion-column-wrapper fusion-column-has-shadow fusion-flex-justify-content-flex-start fusion-content-layout-column\"><div class=\"fusion-title title fusion-title-1 fusion-sep-none fusion-title-text fusion-title-size-two\" style=\"--awb-margin-top:0px;--awb-margin-top-small:10px;--awb-margin-right-small:0px;--awb-margin-bottom-small:10px;--awb-margin-left-small:0px;\"><h2 class=\"fusion-title-heading title-heading-left\" style=\"margin:0;\">Latest news<\/h2><\/div><\/div><\/div><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-2 fusion_builder_column_3_4 3_4 fusion-flex-column\" style=\"--awb-bg-size:cover;--awb-width-large:75%;--awb-margin-top-large:0px;--awb-spacing-right-large:2.56%;--awb-margin-bottom-large:20px;--awb-spacing-left-large:2.56%;--awb-width-medium:75%;--awb-order-medium:0;--awb-spacing-right-medium:2.56%;--awb-spacing-left-medium:2.56%;--awb-width-small:100%;--awb-order-small:0;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;\"><div class=\"fusion-column-wrapper fusion-column-has-shadow fusion-flex-justify-content-flex-start fusion-content-layout-column\"><div class=\"fusion-recent-posts fusion-recent-posts-1 avada-container layout-thumbnails-on-side layout-columns-1\"><section class=\"fusion-columns columns fusion-columns-1 columns-1\"><article class=\"post fusion-column column col col-lg-12 col-md-12 col-sm-12\"><div class=\"recent-posts-content\"><span class=\"vcard\" style=\"display: none;\"><span class=\"fn\"><a href=\"https:\/\/event.eortc.org\/ena2026\/author\/glyn\/\" rel=\"author\">glyn<\/a><\/span><\/span><span class=\"updated\" style=\"display:none;\">2026-11-19T09:49:07+01:00<\/span><h3 class=\"entry-title\"><a href=\"https:\/\/event.eortc.org\/ena2026\/2026\/11\/19\/antibody-drug-conjugate-shows-promising-early-results-in-phase-i-trial-in-sarcoma-patients\/\">Antibody-drug conjugate shows promising early results in phase I trial in sarcoma patients<\/a><\/h3><p class=\"meta\"><span class=\"vcard\" style=\"display: none;\"><span class=\"fn\"><a href=\"https:\/\/event.eortc.org\/ena2026\/author\/glyn\/\" rel=\"author\">glyn<\/a><\/span><\/span><span class=\"updated\" style=\"display:none;\">2026-11-19T09:49:07+01:00<\/span><span>19 November 2026<\/span><span class=\"fusion-inline-sep\">|<\/span><\/p><p>   Antibody-drug conjugate shows promising early results in phase I trial in sarcoma patients 19 November Barcelona, Spain: An antibody-drug conjugate, a type of drug that targets and enters cancer cells like a [...]<\/p><\/div><\/article><article class=\"post fusion-column column col col-lg-12 col-md-12 col-sm-12\"><div class=\"recent-posts-content\"><span class=\"vcard\" style=\"display: none;\"><span class=\"fn\"><a href=\"https:\/\/event.eortc.org\/ena2026\/author\/glyn\/\" rel=\"author\">glyn<\/a><\/span><\/span><span class=\"updated\" style=\"display:none;\">2026-11-19T09:32:23+01:00<\/span><h3 class=\"entry-title\"><a href=\"https:\/\/event.eortc.org\/ena2026\/2026\/11\/19\/new-drug-iacs-6274-shows-promise-in-phase-i-clinical-trial-treating-patients-with-advanced-ovarian-cancer\/\">New drug IACS-6274 shows promise in phase I clinical trial treating patients with advanced ovarian cancer<\/a><\/h3><p class=\"meta\"><span class=\"vcard\" style=\"display: none;\"><span class=\"fn\"><a href=\"https:\/\/event.eortc.org\/ena2026\/author\/glyn\/\" rel=\"author\">glyn<\/a><\/span><\/span><span class=\"updated\" style=\"display:none;\">2026-11-19T09:32:23+01:00<\/span><span>19 November 2026<\/span><span class=\"fusion-inline-sep\">|<\/span><\/p><p>    New drug IACS-6274 shows promise in phase I clinical trial treating patients with advanced ovarian cancer 19 November, Barcelona, Spain: Patients with advanced, hard-to-treat ovarian cancer have responded well to treatment [...]<\/p><\/div><\/article><article class=\"post fusion-column column col col-lg-12 col-md-12 col-sm-12\"><div class=\"recent-posts-content\"><span class=\"vcard\" style=\"display: none;\"><span class=\"fn\"><a href=\"https:\/\/event.eortc.org\/ena2026\/author\/glyn\/\" rel=\"author\">glyn<\/a><\/span><\/span><span class=\"updated\" style=\"display:none;\">2026-11-19T09:53:26+01:00<\/span><h3 class=\"entry-title\"><a href=\"https:\/\/event.eortc.org\/ena2026\/2026\/11\/19\/antibody-drug-conjugate-designed-to-target-tumour-scaffolding-produces-positive-results\/\">Antibody-drug conjugate designed to target tumour \u2018scaffolding\u2019 produces positive results<\/a><\/h3><p class=\"meta\"><span class=\"vcard\" style=\"display: none;\"><span class=\"fn\"><a href=\"https:\/\/event.eortc.org\/ena2026\/author\/glyn\/\" rel=\"author\">glyn<\/a><\/span><\/span><span class=\"updated\" style=\"display:none;\">2026-11-19T09:53:26+01:00<\/span><span>19 November 2026<\/span><span class=\"fusion-inline-sep\">|<\/span><\/p><p>    Antibody-drug conjugate designed to target tumour \u2018scaffolding\u2019 produces positive results in phase I head and neck cancer trial 19 November, Barcelona, Spain: An antibody-drug conjugate (ADC), called micvotabart pelidotin, or MICVO, [...]<\/p><\/div><\/article><\/section><\/div><\/div><\/div><\/div><\/div><div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-3 fusion-flex-container has-pattern-background has-mask-background hundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-padding-top:0px;--awb-padding-bottom:0px;--awb-padding-top-small:0px;--awb-padding-right-small:0px;--awb-padding-left-small:0px;--awb-margin-top:0px;--awb-margin-bottom:0px;--awb-background-color:var(--awb-color1);--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap\" style=\"width:104% !important;max-width:104% !important;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-3 fusion_builder_column_1_1 1_1 fusion-flex-column\" style=\"--awb-padding-top:63px;--awb-padding-top-small:0px;--awb-overflow:hidden;--awb-bg-color:var(--awb-color6);--awb-bg-color-hover:var(--awb-color6);--awb-bg-size:cover;--awb-border-radius:0px 0px 63px 63px;--awb-width-large:100%;--awb-margin-top-large:0px;--awb-spacing-right-large:0px;--awb-margin-bottom-large:20px;--awb-spacing-left-large:0px;--awb-width-medium:100%;--awb-order-medium:0;--awb-spacing-right-medium:0px;--awb-spacing-left-medium:0px;--awb-width-small:100%;--awb-order-small:0;--awb-margin-top-small:0px;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;\" data-scroll-devices=\"small-visibility,medium-visibility,large-visibility\"><div class=\"fusion-column-wrapper fusion-column-has-shadow fusion-flex-justify-content-flex-start fusion-content-layout-column\"><\/div><\/div><\/div><\/div><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"100-width.php","meta":{"footnotes":""},"class_list":["post-1057","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/event.eortc.org\/ena2026\/wp-json\/wp\/v2\/pages\/1057","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/event.eortc.org\/ena2026\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/event.eortc.org\/ena2026\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/event.eortc.org\/ena2026\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/event.eortc.org\/ena2026\/wp-json\/wp\/v2\/comments?post=1057"}],"version-history":[{"count":5,"href":"https:\/\/event.eortc.org\/ena2026\/wp-json\/wp\/v2\/pages\/1057\/revisions"}],"predecessor-version":[{"id":1069,"href":"https:\/\/event.eortc.org\/ena2026\/wp-json\/wp\/v2\/pages\/1057\/revisions\/1069"}],"wp:attachment":[{"href":"https:\/\/event.eortc.org\/ena2026\/wp-json\/wp\/v2\/media?parent=1057"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}